 |
Previous Article | Next Article 
The Journal of Neuroscience, August 1, 2002, 22(15):6388-6393
Peripheral Group II Metabotropic Glutamate Receptors
(mGluR2/3) Regulate Prostaglandin E2-Mediated
Sensitization of Capsaicin Responses and Thermal Nociception
Dongni
Yang1 and
Robert
W.
Gereau IV1, 2
1 Department of Molecular Physiology and Biophysics and
2 Division of Neuroscience, Baylor College of Medicine,
Houston, Texas 77030
 |
ABSTRACT |
Previous studies have shown that group II metabotropic glutamate
receptors (mGluRs) are present on the peripheral terminals of primary
sensory neurons, suggesting that they might be involved in nociception.
In this study, we investigated the modulation of
nociception by peripheral group II mGluRs and the molecular basis of
this modulation. Subcutaneous injection of a group II mGluR agonist,
2R,4R
4-aminopyrrolidine-2,4-dicarboxylate (APDC), did not alter
thermal sensitivity but blocked prostaglandin E2 (PGE2)-induced thermal hyperalgesia. This effect was
blocked by (2s)-2-amino-2-[(1s,2s)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid, a selective group II mGluR antagonist. In cultured primary sensory neurons, APDC blocked PGE2-induced
potentiation of capsaicin responses, which was abolished when neurons
were pretreated with pertussis toxin. Similar potentiating effects induced by forskolin but not 8-bromo-cAMP were also blocked by the
activation of group II mGluRs. These results indicate that peripheral
group II mGluRs act via inhibition of adenylyl cyclase to reverse the
sensitization of capsaicin receptors and the thermal hyperalgesia
induced by PGE2, and suggest that peripheral group II mGluRs might be targeted for therapeutic intervention in
inflammatory pain states.
Key words:
capsaicin; DRG; mGluR; VR1; pain; phosphorylation; PKA; prostanoid; PGE2; inflammation; cAMP
 |
INTRODUCTION |
Inflammatory pain, which is a major
report by patients with inflammation (Levine and Reichling, 1999 ),
usually manifests as an increased response to painful stimuli
(hyperalgesia) and pain sensation to previously innocuous stimuli
(allodynia). During inflammation, a number of molecules, including
prostaglandins, bradykinin, substance P, and others, are released into
the injury site. Many of these inflammatory mediators sensitize primary
afferent nociceptors via the cAMP/PKA pathway. Activation of adenylyl
cyclase (AC) or PKA produces hyperalgesia, whereas PKA inhibitors
reduce hyperalgesia (Taiwo and Levine, 1991 ). One mechanism by which the cAMP/PKA pathway could induce sensitization is by modulating the
principle channels that transduce sensory stimuli.
The vanilloid receptor 1 (VR1), also known as the capsaicin receptor,
is a nonselective cation channel expressed predominantly in sensory
neurons that functions to integrate a number of pain-inducing stimuli
(Caterina et al., 1997 ; Tominaga et al., 1998 ). VR1 is essential for
inflammatory thermal hyperalgesia, because inflammation-induced thermal
sensitization fails to develop in mice lacking VR1 (Caterina et al.,
2000 ; Davis et al., 2000 ). Prostaglandin E2
(PGE2), by activating
Gs to activate the cAMP/PKA pathway,
enhances capsaicin receptor function (Pitchford and Levine, 1991 ;
Lopshire and Nicol, 1997 ); this effect may mediate thermal hyperalgesia.
In addition to the well known inflammatory mediators mentioned above,
glutamate is also released in peripheral tissues during inflammation
(Omote et al., 1998 ; deGroot et al., 2000 ). Glutamate activates
ionotropic glutamate receptors (iGluRs), including NMDA, AMPA, and
kainate receptors, as well as G-protein-coupled metabotropic glutamate
receptors (mGluRs). Peripheral injection of glutamate induces
mechanical and thermal hypersensitivity by activating both iGluRs and
mGluRs (Carlton et al., 1995 ; Jackson et al., 1995 ; Zhou et al., 1996 ;
Bhave et al., 2001 ; Walker et al., 2001 ).
Based on sequence homology and pharmacological properties, mGluRs are
divided into three groups: group I (mGluR1 and mGluR5), group II
(mGluR2 and mGluR3), and group III (mGluR4, mGluR6, mGluR7, and
mGluR8). Group I mGluRs are localized on nociceptive primary afferent
fibers in the skin; activation of peripheral group I mGluRs enhances
nociception (Bhave et al., 2001 ; Walker et al., 2001 ). Group II mGluRs
are also expressed on primary afferent terminals (Carlton et al.,
2001 ), but the role of peripheral group II mGluRs in nociception
remains unknown. Systemic administration of group II mGluR agonists
reduces inflammatory hyperalgesia (Sharpe et al., 2002 ). We hypothesize
that group II mGluR agonists may act through peripheral mechanisms to
reduce nociception.
The necessity for the cAMP/PKA pathway in inflammatory hyperalgesia
suggests that Gi-coupled receptors might be
targeted to reduce pain. Indeed, activation of
Gi-coupled µ-opioid and adenosine receptors
produces analgesic effects (Joris et al., 1987 ; Taiwo and Levine, 1990 ;
Karlsten et al., 1992 ). Because group II mGluRs are coupled to
Gi, one mechanism by which group II mGluR
agonists could reduce hyperalgesia is by inhibiting the cAMP/PKA
pathway. The present study examined this hypothesis both in
vivo and in vitro and demonstrated that peripheral
group II mGluRs regulate PGE2-mediated
sensitization, possibly by reversing PGE2-induced modulation of capsaicin receptors.
 |
MATERIALS AND METHODS |
Behavioral testing. Male ICR mice (6-8 weeks
of age; Taconic, Germantown, NY) were allowed to recover for at
least 2 d after arrival and habituated for at least 3 hr before
experiments. Six mice were tested at approximately the same time on
different days and divided into three groups with three different treatments.
Thermal sensitivity was measured as described previously (Bhave et al.,
2001 ). A light beam was applied to the plantar surface of the hindpaw
(IITC Life Sciences, Woodland Hills, CA), and the foot
withdrawal latency was measured. Before injections, baseline (time 0)
was measured three times at an interval of ~10 min and averaged.
After injections, withdrawal latency was measured at 30 min, 45 min, 1 hr, 1.5 hr, and 3 hr.
Stock solutions of 100 mM
(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate
(APDC) and 0.1 mM
(2s)-2-amino-2-[(1s,2s)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) (both from Tocris Cookson, Ballwin, MO) were made in 1 and 1.2 eq NaOH, respectively. A stock
solution of 10 mg/ml PGE2 (Sigma, St. Louis,
MO) was made in 100% ethanol. All drugs were diluted in
0.1 M PBS, pH 7.4. An equal amount of 100 mM HCl was added when diluting APDC to adjust the
pH. All drugs were injected subcutaneously in a volume of 10 µl into
the plantar surface of the hindpaw. Appropriate vehicles were prepared as the diluents for each drug.
Cell culture. DRGs were isolated from 4- to 6-week-old ICR
mice. Isolated ganglia were placed into 4°C PBS without
Mg2+ or Ca2+
(Invitrogen, Paisley, UK). Ganglia were incubated in 15 U/ml papain/L-cysteine (Worthington, Freehold, NJ) in
HBSS (Invitrogen) for 20 min at 37°C, then washed with HBSS
three times, followed by a 20 min incubation at 37°C in 1.5 mg/ml
collagenase (Sigma) in HBSS. Ganglia were washed with HBSS three times
before trituration with fire-polished Pasteur pipets. Dissociated cells
were plated at ~3000 cells/well on 12 mm glass coverslips coated with
poly-D-lysine and collagen (Sigma). Cells were
cultured for 5-6 d at 37°C in humidified air with 5%
CO2. The culture medium contained neurobasal medium, 10% FBS, 100 U/ml penicillin/streptomycin, and 2 mM Glutamax (all from Invitrogen). In experiments
in which pertussis toxin (PTX; Sigma) was used, 500 ng/ml PTX
was added into the medium the night before.
Calcium imaging. Cells were loaded with 10 ng/ml fura-2 AM
(Molecular Probes, Eugene, OR) in HBSS for 1 hr and then washed three
times and incubated in fresh HBSS for ~45 min before the experiments
were performed. A coverslip was placed in the perfusion chamber (~200
µl volume) and perfused with HBSS at 2 ml/min. Cells were viewed
under an inverted 1×70 microscope (Olympus Optical, Tokyo, Japan).
Images were captured with a Hamamatsu (Shizouka, Japan) Orca cooled
charge-coupled device camera and recorded and analyzed using the
SimplePCI software package with the dynamic intensity analysis module
(Compix, Tualatin, OR). Traces are all expressed as the ratio of
fluorescence emission at an excitation wavelength of 357 and 380 nm,
respectively. All experiments were performed at room temperature.
Drug application.
(2R,4R)-APDC, LY341495, and
PGE2 stock solutions were made as described
above. Capsaicin (Sigma) stock solution was made in ethanol. Forskolin
(Sigma) stock solution was made in DMSO. IBMX (Sigma) and 8-bromo-cAMP
(Sigma) stock solutions were made in deionized water. All drugs were
diluted to final concentrations in HBSS and applied via bath perfusion.
Data analysis. Off-line analysis was performed using
Microcal Origin (Microcal Software, Inc., Northampton, MA). Data
are expressed as means ± SEM. Treatment effects were analyzed by
one-way ANOVA followed by Tukey's post hoc multiple
comparisons using GraphPad Prism (GraphPad Software Inc., San Diego,
CA). The time course of the effects of PGE2 was
analyzed by two-way ANOVA followed by Bonferroni post-tests. Error
probabilities of p < 0.05 were considered
statistically significant.
 |
RESULTS |
Activation of peripheral group II metabotropic glutamate receptors
blocks prostaglandin E-induced thermal hyperalgesia
To test whether peripheral group II mGluRs can regulate thermal
nociception, APDC, a selective group II mGluR agonist, was injected
subcutaneously into the plantar surface of a mouse hindpaw. As shown in
Figure 1b, APDC did not alter
baseline thermal withdrawal latency, which is consistent with previous
reports (Walker et al., 2001 ; Sharpe et al., 2002 ). To test the
hypothesis that group II mGluRs could play a role in nociception when
responses to heat are sensitized by the activation of
Gs-coupled receptors, 100 ng of
PGE2 was injected subcutaneously into the plantar
surface of the hindpaw to induce thermal hyperalgesia.
PGE2-induced thermal hyperalgesia lasted >1 hr
and peaked at or before 30 min (Fig. 1a), which is
consistent with previous results (Kerr et al., 2001 ). Coinjection of
APDC with PGE2 blocked
PGE2-induced thermal hyperalgesia (Fig.
1b). LY341495, a selective group II mGluR antagonist,
completely blocked the APDC effect (Fig. 1b). Three hours
after injection, when PGE2-induced hyperalgesia
had recovered, all groups showed no significant difference from the
baseline (Fig. 1c).

View larger version (40K):
[in this window]
[in a new window]
|
Figure 1.
Activation of peripheral group II mGluRs blocks
PGE2-induced thermal hyperalgesia. a,
PGE2 (100 ng in 10 µl) injected subcutaneously into the
plantar surface of a mouse hindpaw decreased withdrawal latency to
radiant heat applied to the hindpaw. Asterisks indicate
time points at which PGE2 (n = 6) was
significantly different from vehicle (n = 7).
b, Normalized thermal withdrawal latencies at 0.5, 0.75, and 1 hr were averaged and compared with baseline values. Injection of
APDC (20 ng in 10 µl; n = 6) had no effect alone,
but coinjection of APDC (n = 6) blocked
PGE2-induced hyperalgesia. LY341495 (0.2 ng in 10 µl;
n = 7) blocked the APDC effect. c,
At 3 hr, all groups were statistically indistinguishable from baseline.
In all panels, dashed lines indicate the basal
response.
|
|
Group II metabotropic glutamate receptors block prostaglandin
E2-induced sensitization of capsaicin responses
The above results suggest that activation of peripheral group II
mGluRs does not affect basal thermal sensitivity but blocks PGE2-induced thermal hyperalgesia. The VR1, or
capsaicin receptor, is a key component of the thermal transduction
machinery; it is critical for the development of thermal hyperalgesia
(Caterina et al., 1997 ; Tominaga et al., 1998 ; Davis et al., 2000 ).
PGE2 sensitizes capsaicin receptors by activating
the cAMP/PKA pathway (Pitchford and Levine, 1991 ; Lopshire and Nicol,
1998 ). To test the hypothesis that group II mGluRs block
PGE2-induced thermal hyperalgesia by blocking
PGE2-induced potentiation of capsaicin receptor
function, we investigated the effects of PGE2 and
APDC on capsaicin responses in cultured mouse DRG neurons.
VR1 is a cation channel that allows Na2+
and Ca2+ influx when activated by heat,
protons, or capsaicin. Therefore, we studied VR1 function by measuring
capsaicin-induced calcium influx into DRG neurons. In 20% of DRG
neurons, application of capsaicin induced increases in intracellular
Ca2+ of varying amplitude and duration.
Neurons with responses <10 min in duration were included in this study
(Fig. 2). Ten minutes after the first
capsaicin application, a second identical capsaicin application
produced a smaller response than the first, indicating desensitization
of capsaicin receptors. The ratio of the amplitude of the second
response to that of the first was calculated as the "response
ratio."

View larger version (28K):
[in this window]
[in a new window]
|
Figure 2.
Group II mGluRs block PGE2 enhancement
of capsaicin receptor function. a, Representative traces
of capsaicin-induced calcium responses recorded from cultured DRG
neurons; 20 nM capsaicin was applied twice
(bars below the traces; 21 sec each), inducing
pronounced desensitization of the calcium response. PGE2
(200 nM, 7 min) decreased this desensitization of capsaicin
responses (note the arrows compared with control). APDC
(10 µM) blocked the PGE2 effect, and LY341495
(100 nM) blocked the APDC effect. Dashed lines
show the peaks of the responses. b, Means ± SEM for the data shown in a;
n = 28-60; *p < 0.05.
|
|
As shown in Figure 2, when PGE2 was applied
between the two capsaicin responses, the response ratio was
significantly increased (p < 0.001; ANOVA).
When APDC alone was applied, there was no significant change in
desensitization (Fig. 2), which is consistent with our behavioral
result that APDC did not change baseline thermal sensitivity. However,
when APDC was coapplied with PGE2, the response ratio was significantly decreased compared with cells treated with
PGE2 (p < 0.05; ANOVA).
LY341495, a selective group II mGluR antagonist, completely blocked the
effect of APDC (p < 0.05), suggesting that the
effects of APDC were attributable to the activation of group II mGluRs.
Group II metabotropic glutamate receptors block prostaglandin
E2 sensitization of capsaicin responses by activating
Gi and inhibiting AC
To test the hypothesis that group II mGluRs function by activating
Gi, we treated cells with PTX (500 ng/ml
overnight) before calcium-imaging experiments. PTX induces ADP
ribosylation of Gi and impairs the interaction of
Gi with receptor-ligand complexes, uncoupling
receptors from downstream second messenger systems (Hsia et al., 1984 ;
Moss and Vaughan, 1984 ). Treatment with PTX did not affect capsaicin
responses or the effects of PGE2, whereas the
effect of APDC was abolished (Fig.
3).

View larger version (52K):
[in this window]
[in a new window]
|
Figure 3.
Group II mGluRs block PGE2 enhancement
of capsaicin receptor function via a PTX-sensitive G-protein.
a, Representative traces of the effect of
PGE2 (200 nM, 7 min) in the presence and
absence of APDC (10 µM) in cells treated with PTX (500 ng/ml, overnight). In PTX-treated cells, PGE2 enhanced
capsaicin responses, but APDC failed to block the PGE2
effects. Bars below traces represent time of capsaicin
application. b, Means ± SEM;
n = 51-73; *p < 0.05.
|
|
Previous experiments suggest that group II mGluRs function by
activating Gi. To test the hypothesis that APDC
blocks PGE2-induced sensitization by
inhibiting AC, we investigated whether activation of group II mGluRs
could block the effects of forskolin. Forskolin directly activates AC
(Birnbaumer et al., 1983 ), and this effect of forskolin can be
inhibited by activation of Gi (Hildebrandt et
al., 1982 ). cAMP synthesized by AC is rapidly metabolized within cells.
To increase and prolong the effect of forskolin, we coapplied IBMX, an
inhibitor of cAMP phosphodiesterase. Application of forskolin plus IBMX
produced effects similar to those of PGE2 (Fig.
4). Application of APDC blocked the
ability of forskolin to enhance capsaicin responses.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 4.
Group II mGluRs block sensitization induced
by the activation of AC but not sensitization induced by the direct
activation of PKA. a, Representative traces of the
effect of forskolin (50 µM) plus IBMX (100 µM) (7 min) in the absence and presence of APDC (10 µM). Forskolin produced an enhancement of capsaicin
responses similar to that of PGE2, which was blocked
by APDC. b, Representative traces of the effect of
8-bromo-cAMP (100 µM) (7 min) in the absence and presence
of APDC (10 µM). 8-bromo-cAMP produced an enhancement of
capsaicin responses similar to that of PGE2, and
this enhancement was not reduced by APDC. Bars below traces
represent time of capsaicin application. c,
Means ± SEM; n = 30-47 for each group;
*p < 0.05. Fsk, Forskolin.
|
|
The results described above suggest that group II mGluRs block
sensitization by PGE2 or forskolin at or
downstream of AC. Because IBMX is present, group II mGluRs were not
acting on phosphodiesterases. To rule out the possibility that group II
mGluRs are acting on PKA or other downstream effectors, we used
8-bromo-cAMP, a nonhydrolyzable analog of cAMP, to modulate capsaicin
receptors. 8-Bromo-cAMP produced effects similar to those of
PGE2 (Fig. 4). However, the effects of
8-bromo-cAMP were not blocked by APDC, suggesting that group II mGluRs
are not acting on PKA or its downstream targets.
 |
DISCUSSION |
Agonists of group II mGluRs have been shown to act systemically as
analgesics (Sharpe et al., 2002 ). Furthermore, these drugs depress
excitatory synaptic transmission in the substantia gelatinosa (Gerber
et al., 2000 ) and block capsaicin-induced central sensitization in
spinothalamic tract neurons (Neugebauer et al., 2000 ). The observation that group II mGluRs are expressed on peripheral terminals of primary sensory neurons suggests that they might also act
peripherally to produce antinociceptive effects. Here we have shown
that group II mGluRs do not affect basal thermal nociception, but that
activation of these receptors blocks the development of hyperalgesia
induced by PGE2.
The fact that group II mGluRs couple to Gi and
the fact that the cAMP/PKA pathway is critical in the sensitization of
nociception led us to hypothesize that the mechanism by which group II
mGluRs block PGE2-induced thermal hyperalgesia is
via inhibition of AC. PGE2 significantly
decreased desensitization of capsaicin-induced Ca2+ influx in sensory neurons. Activation
of group II mGluRs did not change capsaicin responses but significantly
attenuated PGE2-induced sensitization, which is
consistent with our findings that APDC had no effect on basal thermal
sensation but did block PGE2-induced hyperalgesia. PTX treatment abolished this APDC effect. In agreement with previous reports that PGE2 exerts its
effects via the cAMP/PKA pathway, application of forskolin or
8-bromo-cAMP also sensitized capsaicin responses. Group II mGluR
activation blocked the effects of forskolin plus IBMX but not the
effect of 8-bromo-cAMP. These results indicate that group II mGluRs
block PGE2-induced sensitization by activating
Gi and inhibiting AC.
Although there are many Gi-coupled receptors,
their inhibitory effects on AC were characterized primarily in
heterologous expression systems in which overexpression of a protein
might produce nonphysiological effects. Only in a very few cases have the physiological functions of a Gi-coupled
receptor been shown to be attributable to the inhibition of AC. Group
II mGluRs are coupled to Gi. In the CNS, the
mechanism of these effects is poorly understood, despite the fact that
they have been shown to produce various effects, including presynaptic
modulation of synaptic transmission (Macek et al., 1996 ) and regulation
of long-term depression and long-term potentiation (O'Leary and
O'Connor, 1998 ; Otani et al., 1999 ). The present study indicates that
peripheral group II mGluRs attenuate PGE2-induced
thermal hyperalgesia and suggests that this effect is mediated by
blocking PGE2-mediated enhancement of capsaicin
responses. Our results also indicate that this was attributable to the
activation of Gi and inhibition of AC after group
II mGluR activation. Many inflammatory mediators, including
PGE2 (Cui and Nicol, 1995 ; Hingtgen et al., 1995 ;
Mnich et al., 1995 ), prostaglandin I2 (Murata et
al., 1997 ), adenosine (Sawynok et al., 1997 ), serotonin (Taiwo and
Levine, 1992 ), and 8R,15S-dihydroxyeicosatetraenoic
acid (Levine et al., 1986 ), activate the cAMP/PKA pathway to
induce hyperalgesia. Group II mGluR agonists are likely to inhibit the
production of cAMP induced by other inflammatory mediators and,
accordingly, might reduce the nociceptive sensitization induced by
these agents.
It is interesting to note that the expression of group II mGluRs
changes in several pain models. L-Acetylcarnitine, an
analgesic used to treat neuropathic pain, acts by upregulating mGluR2
in DRG neurons (Chiechio et al., 2002 ). UV-irradiation-induced
peripheral inflammation increases the expression of mGluR3 mRNA in the
dorsal horn (Boxall et al., 1998 ). mGluR3 mRNA is increased in the
cerebral cortex of monoarthritic rats (Neto et al., 2001 ). Although our results suggest that activation of peripheral group II mGluRs can fully
block PGE2-induced thermal hyperalgesia, it would
be interesting to investigate whether they have more significant effects in prolonged pain models.
We have shown recently that peripheral group I mGluRs also
modulate nociception. Peripherally applied
(RS)-3,5-dihydroxyphenylglycine, a selective group I
mGluR agonist, dose-dependently induces thermal hyperalgesia;
antagonists of group I mGluRs can prevent and attenuate formalin-induced pain (Bhave et al., 2001 ). The present data indicate that peripheral group II mGluRs play an opposing role in modulating nociception. During inflammation, glutamate is released into the peripheral injury site and is thought to play a role in inducing inflammatory pain. Although it is unknown whether group I mGluRs and
group II mGluRs are colocalized in the same peripheral sensory afferents, the activation of group II mGluRs might act as a balancing mechanism to counteract some of the effects of glutamate. It would be
interesting to investigate whether group II mGluRs provide tonic
inhibition of nociception and whether inhibition of group II mGluRs
would result in more significant nociceptive sensitization. As
mentioned above, the expression of group II mGluRs increases in several
pain models; this might act as a protective mechanism to prevent
additional sensitization of nociception in situations in which
nociceptive thresholds are already decreased. Additional experiments
will need to be performed to investigate whether glutamate acts to
induce hyperalgesia at the beginning of inflammation while at the same
time producing an analgesic effect during prolonged inflammation when
there are more group II mGluRs present.
Our study is the first to demonstrate a role for peripheral group II
mGluRs in the modulation of nociception. These results do not rule out
the possibility that group II mGluRs also modulate inflammatory pain
through central mechanisms. However, our results indicate that
activation of peripheral group II mGluRs completely blocks the thermal
hyperalgesia induced by PGE2. In addition to the
induction of inflammatory pain, PGE2 might also
contribute to the maintenance or progression of inflammatory pain,
because inflammation can be accompanied by a sustained increase in
PGE2 levels (Davies et al., 1984 ). Peripheral
group II mGluRs can potentially be targeted to control inflammatory
pain while at the same time avoiding the possible CNS side effects of
systemic administration.
 |
FOOTNOTES |
Received March 29, 2002; revised May 7, 2002; accepted May 16, 2002.
This work was supported by grants from the National Institute of Mental
Health (MH60230) (R.G.) and the National Institute of Neurological
Disorders and Stroke (NS42595). We thank G. Bhave and F. Karim for
helpful comments on this manuscript.
Correspondence should be addressed to Dr. Robert W. Gereau
IV, Division of Neuroscience, Baylor College of Medicine, Houston, TX 77030. E-mail: rgereau{at}bcm.tmc.edu.
 |
REFERENCES |
-
Bhave G,
Karim F,
Carlton SM,
Gereau RW
(2001)
Peripheral group I metabotropic glutamate receptors modulate nociception in mice.
Nat Neurosci
4:417-423[Web of Science][Medline].
-
Birnbaumer L,
Stengel D,
Desmier M,
Hanoune J
(1983)
Forskolin regulation of liver membrane adenylyl cyclase.
Eur J Biochem
136:107-112[Medline].
-
Boxall SJ,
Berthele A,
Laurie DJ,
Sommer B,
Zieglgansberger W,
Urban L,
Tolle TR
(1998)
Enhanced expression of metabotropic glutamate receptor 3 messenger RNA in the rat spinal cord during ultraviolet irradiation induced peripheral inflammation.
Neuroscience
82:591-602[Web of Science][Medline].
-
Carlton SM,
Hargett GL,
Coggeshall RE
(1995)
Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin.
Neurosci Lett
197:25-28[Web of Science][Medline].
-
Carlton SM,
Hargett GL,
Coggeshall RE
(2001)
Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat.
Neuroscience
105:957-969[Medline].
-
Caterina MJ,
Schumacher MA,
Tominaga M,
Rosen TA,
Levine JD,
Julius D
(1997)
The capsaicin receptor: a heat-activated ion channel in the pain pathway.
Nature
389:816-824[Medline].
-
Caterina MJ,
Leffler A,
Malmberg AB,
Martin WJ,
Trafton J,
Petersen-Zeitz KR,
Koltzenburg M,
Basbaum AI,
Julius D
(2000)
Impaired nociception and pain sensation in mice lacking the capsaicin receptor.
Science
288:306-313[Abstract/Free Full Text].
-
Chiechio S,
Caricasole A,
Barletta E,
Storto M,
Catania MV,
Copani A,
Vertechy M,
Nicolai R,
Calvani M,
Melchiorri D,
Nicoletti F
(2002)
L-Acetylcarnitine induces analgesia by selectively upregulating mGlu2 metabotropic glutamate receptors.
Mol Pharmacol
61:989-996[Abstract/Free Full Text].
-
Cui M,
Nicol GD
(1995)
Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons.
Neuroscience
66:459-466[Web of Science][Medline].
-
Davies P,
Bailey PJ,
Goldenberg MM,
Ford-Hutchinson AW
(1984)
The role of arachidonic acid oxygenation products in pain and inflammation.
Annu Rev Immunol
2:335-357[Web of Science][Medline].
-
Davis JB,
Gray J,
Gunthorpe MJ,
Hatcher JP,
Davey PT,
Overend P,
Harries MH,
Latcham J,
Clapham C,
Atkinson K,
Hughes SA,
Rance K,
Grau E,
Harper AJ,
Pugh PL,
Rogers DC,
Bingham S,
Randall A,
Sheardown SA
(2000)
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia.
Nature
405:183-187[Medline].
-
deGroot J,
Zhou S,
Carlton SM
(2000)
Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation.
NeuroReport
11:497-502[Web of Science][Medline].
-
Gerber G,
Zhong J,
Youn D,
Randic M
(2000)
Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn.
Neuroscience
100:393-406[Web of Science][Medline].
-
Hildebrandt JD,
Hanoune J,
Birnbaumer L
(1982)
Guanine nucleotide inhibition of cyc-S49 mouse lymphoma cell membrane adenylyl cyclase.
J Biol Chem
257:14723-14725[Abstract/Free Full Text].
-
Hingtgen CM,
Waite KJ,
Vasko MR
(1995)
Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade.
J Neurosci
15:5411-5419[Abstract].
-
Hsia JA,
Moss J,
Hewlett EL,
Vaughan M
(1984)
ADP-ribosylation of adenylate cyclase by pertussis toxin. Effects on inhibitory agonist binding.
J Biol Chem
259:1086-1090[Abstract/Free Full Text].
-
Jackson DL,
Graff CB,
Richardson JD,
Hargreaves KM
(1995)
Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats.
Eur J Pharmacol
284:321-325[Web of Science][Medline].
-
Joris JL,
Dubner R,
Hargreaves KM
(1987)
Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation?
Anesth Analg
66:1277-1281[Abstract/Free Full Text].
-
Karlsten R,
Gordh T,
Post C
(1992)
Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice.
Pharmacol Toxicol
70:434-438[Medline].
-
Kerr BJ,
Souslova V,
McMahon SB,
Wood JN
(2001)
A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain.
NeuroReport
12:3077-3080[Web of Science][Medline].
-
Levine JD,
Reichling DB
(1999)
Peripheral mechanisms of inflammatory pain.
In: Textbook of pain (Wall PD,
Melzack R,
eds), pp 59-84. Edinburgh: Churchill Livingstone.
-
Levine JD,
Lam D,
Taiwo YO,
Donatoni P,
Goetzl EJ
(1986)
Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid.
Proc Natl Acad Sci USA
83:5331-5334[Abstract/Free Full Text].
-
Lopshire JC,
Nicol GD
(1997)
Activation and recovery of the PGE2-mediated sensitization of the capsaicin response in rat sensory neurons.
J Neurophysiol
78:3154-3164[Abstract/Free Full Text].
-
Lopshire JC,
Nicol GD
(1998)
The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies.
J Neurosci
18:6081-6092[Abstract/Free Full Text].
-
Macek T,
Winder D,
Gereau R,
Ladd C,
Conn P
(1996)
Differential involvement of group II and group III mGluRs as autoreceptors.
J Neurophysiol
76:3798-3806[Abstract/Free Full Text].
-
Mnich SJ,
Veenhuizen AW,
Monahan JB,
Sheehan KC,
Lynch KR,
Isakson PC,
Portanova JP
(1995)
Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2.
J Immunol
155:4437-4444[Abstract].
-
Moss J,
Vaughan M
(1984)
Toxin ADP-ribosyltransferases that act on adenylate cyclase systems.
Methods Enzymol
106:411-418[Medline].
-
Murata T,
Ushikubi F,
Matsuoka T,
Hirata M,
Yamasaki A,
Sugimoto Y,
Ichikawa A,
Aze Y,
Tanaka T,
Yoshida N,
Ueno A,
Oh-ishi S,
Narumiya S
(1997)
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor.
Nature
388:678-682[Medline].
-
Neto FL,
Schadrack J,
Platzer S,
Zieglgansberger W,
Tolle TR,
Castro-Lopes JM
(2001)
Up-regulation of metabotropic glutamate receptor 3 mRNA expression in the cerebral cortex of monoarthritic rats.
J Neurosci Res
63:356-367[Medline].
-
Neugebauer V,
Chen PS,
Willis WD
(2000)
Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate STT cells.
J Neurophysiol
84:2998-3009[Abstract/Free Full Text].
-
O'Leary DM,
O'Connor JJ
(1998)
Priming of long-term potentiation by prior activation of group I and II metabotropic glutamate receptors in the rat dentate gyrus in vitro.
Brain Res
809:91-96[Web of Science][Medline].
-
Omote K,
Kawamata T,
Kawamata M,
Namiki A
(1998)
Formalin-induced release of excitatory amino acids in the skin of the rat hindpaw.
Brain Res
787:161-164[Web of Science][Medline].
-
Otani S,
Auclair N,
Desce JM,
Roisin MP,
Crepel F
(1999)
Dopamine receptors and group I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases.
J Neurosci
19:9788-9802[Abstract/Free Full Text].
-
Pitchford S,
Levine JD
(1991)
Prostaglandins sensitize nociceptors in cell culture.
Neurosci Lett
132:105-108[Web of Science][Medline].
-
Sawynok J,
Zarrindast MR,
Reid AR,
Doak GJ
(1997)
Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine.
Eur J Pharmacol
333:1-7[Web of Science][Medline].
-
Sharpe EF,
Kingston AE,
Lodge D,
Monn JA,
Headley PM
(2002)
Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo.
Br J Pharmacol
135:1255-1262[Web of Science][Medline].
-
Taiwo YO,
Levine JD
(1990)
Direct cutaneous hyperalgesia induced by adenosine.
Neuroscience
38:757-762[Web of Science][Medline].
-
Taiwo YO,
Levine JD
(1991)
Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia.
Neuroscience
44:131-135[Web of Science][Medline].
-
Taiwo YO,
Levine JD
(1992)
Serotonin is a directly-acting hyperalgesic agent in the rat.
Neuroscience
48:485-490[Web of Science][Medline].
-
Tominaga M,
Caterina MJ,
Malmberg AB,
Rosen TA,
Gilbert H,
Skinner K,
Raumann BE,
Basbaum AI,
Julius D
(1998)
The cloned capsaicin receptor integrates multiple pain-producing stimuli.
Neuron
21:531-543[Web of Science][Medline].
-
Walker K,
Reeve A,
Bowes M,
Winter J,
Wotherspoon G,
Davis A,
Schmid P,
Gasparini F,
Kuhn R,
Urban L
(2001)
mGlu5 receptors and nociceptive function. II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia.
Neuropharmacology
40:10-19[Web of Science][Medline].
-
Zhou S,
Bonasera L,
Carlton SM
(1996)
Peripheral administration of NMDA, AMPA, or KA results in pain behaviors in rats.
NeuroReport
7:895-900[Web of Science][Medline].
Copyright © 2002 Society for Neuroscience 0270-6474/02/22156388-06$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
S. Chiechio, M. Zammataro, M. E. Morales, C. L. Busceti, F. Drago, R. W. Gereau IV, A. Copani, and F. Nicoletti
Epigenetic Modulation of mGlu2 Receptors by Histone Deacetylase Inhibitors in the Treatment of Inflammatory Pain
Mol. Pharmacol.,
May 1, 2009;
75(5):
1014 - 1020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Schnizler, L. P. Shutov, M. J. Van Kanegan, M. A. Merrill, B. Nichols, G. S. McKnight, S. Strack, J. W. Hell, and Y. M. Usachev
Protein Kinase A Anchoring via AKAP150 Is Essential for TRPV1 Modulation by Forskolin and Prostaglandin E2 in Mouse Sensory Neurons
J. Neurosci.,
May 7, 2008;
28(19):
4904 - 4917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Li and V. Neugebauer
Differential Changes of Group II and Group III mGluR Function in Central Amygdala Neurons in a Model of Arthritic Pain
J Neurophysiol,
October 1, 2006;
96(4):
1803 - 1815.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|